Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-K/A
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
10-Q/A
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
News
TYPE
HEADLINE
FILED AT
8-K/A
Audited 2025 financial statements show revenue rising modestly, net income falling to $9.8 million, and members’ equity increasing to $75.5 million
8-K
Aspire-Lakewood Holdings, Inc. Dismisses Turner Stone & Company and Appoints CBIZ CPAs as New Independent Accountant
8-K
Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program
8-K
Aspire Biopharma Holdings, Inc. Announces Corporate Name Change to Aspire-Lakewood Holdings, Inc.
8-K
Aspire Biopharma Holdings, Inc. Releases Investor Presentation
8-K
Aspire Biopharma Completes Acquisition of Dura Driver Control Systems
Prospectus
TYPE
HEADLINE
FILED AT
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]
425
Form 425 - Prospectuses and communications, business combinations
425
Form 425 - Prospectuses and communications, business combinations
425
Form 425 - Prospectuses and communications, business combinations
425
Form 425 - Prospectuses and communications, business combinations
425
Form 425 - Prospectuses and communications, business combinations
Registrations
TYPE
HEADLINE
FILED AT
S-1/A
SHARE RESALE REGISTRATION + SPA
S-1
SHARE RESALE REGISTRATION
S-1
Arena SPA - The price at which Aspire Biopharma Holdings, Inc. sells shares to Arena Business Solutions Global SPC II, Ltd. is determined as ninety-six percent (96%) of the Volume Weighted Average Price (VWAP) of Aspire's common stock during the trading day commencing on the date of the Advance Notice. The amount of shares to be sold is selected by Aspire in each Advance Notice, but it cannot exceed the Maximum Advance Amount defined in the ELOC Agreement, and must comply with the Ownership Limitation, which prevents Arena and its affiliates from owning more than a specified percentage of Aspire's common stock.
S-1/A
SHARE RESALE REGISTRATION
S-1
SHARE RESALE REGISTRATION
S-1
SHARE RESALE REGISTRATION
Proxies
TYPE
HEADLINE
FILED AT
DEFR14A
Form DEFR14A - Revised definitive proxy soliciting materials
